Insilico Medicine Company
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Investors
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
(Reupload).png)
.png)
.png)
Technology:
Artificial Intelligence, Biotechnology, Genetics, Health Care, Pharmaceutical
Industry:
Early Drug Development
Headquarters:
Hong Kong, Hong Kong Island, Hong Kong
Founded Date:
2014-01-01
Employees Number:
11-50
Funding Status:
Late Stage Venture
Investors Number:
27
Total Funding:
306.3
Estimated Revenue:
Less than $1M
Last Funding Date:
6/22/2021
Last Funding Type:
Series C
Register and Claim Ownership